NEW YORK (GenomeWeb) – WaferGen Biosystems is preparing to sell an undisclosed amount of Class A and Class B units to raise up to $34.5 million in a public offering, according to a document filed with the US Securities and Exchange Commission.

In a Form S-1 filed Aug. 14, the firm said it will offer an undisclosed number of Class A units, consisting of shares of the firm's common stock and warrants to purchase shares of common stock. Each warrant will allow the holder to purchase one share of WaferGen's stock at an exercise price still to be determined.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.